메뉴 건너뛰기




Volumn 16, Issue 4, 2007, Pages 861-871

Current Immunotherapeutic Strategies in Prostate Cancer

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; DOCETAXEL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HUJ591; IPILIMUMAB; LUTETIUM 177; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; PROSTVAC VF; RITUXIMAB; SIPULEUCEL T; UNCLASSIFIED DRUG; YTTRIUM 90;

EID: 36049027831     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2007.07.009     Document Type: Review
Times cited : (2)

References (50)
  • 2
    • 0036559864 scopus 로고    scopus 로고
    • A history of prostate cancer treatment
    • Denmeade S.R., and Isaacs J.T. A history of prostate cancer treatment. Nat Rev Cancer 2 (2002) 389-396
    • (2002) Nat Rev Cancer , vol.2 , pp. 389-396
    • Denmeade, S.R.1    Isaacs, J.T.2
  • 3
    • 33845673431 scopus 로고    scopus 로고
    • Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues
    • Gomella L.G. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues. BJU Int 99 Suppl 1 (2007) 25-29
    • (2007) BJU Int , vol.99 , Issue.SUPPL. 1 , pp. 25-29
    • Gomella, L.G.1
  • 4
    • 0033952191 scopus 로고    scopus 로고
    • Clinical states in prostate cancer: toward a dynamic model of disease progression
    • Scher H.I., and Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 55 (2000) 323-327
    • (2000) Urology , vol.55 , pp. 323-327
    • Scher, H.I.1    Heller, G.2
  • 5
    • 4744366279 scopus 로고    scopus 로고
    • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    • Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
    • (2004) N Engl J Med , vol.351 , pp. 1502-1512
    • Tannock, I.F.1    de Wit, R.2    Berry, W.R.3
  • 6
    • 4744337716 scopus 로고    scopus 로고
    • Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
    • Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
    • (2004) N Engl J Med , vol.351 , pp. 1513-1520
    • Petrylak, D.P.1    Tangen, C.M.2    Hussain, M.H.3
  • 7
    • 0019461193 scopus 로고
    • Prostate tumor biology and cell kinetics-theory
    • Coffey D.S., and Isaacs J.T. Prostate tumor biology and cell kinetics-theory. Urology 17 (1981) 40-53
    • (1981) Urology , vol.17 , pp. 40-53
    • Coffey, D.S.1    Isaacs, J.T.2
  • 8
    • 0036682376 scopus 로고    scopus 로고
    • Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer
    • Rhodes D.R., Barrette T.R., Rubin M.A., et al. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 62 (2002) 4427-4433
    • (2002) Cancer Res , vol.62 , pp. 4427-4433
    • Rhodes, D.R.1    Barrette, T.R.2    Rubin, M.A.3
  • 9
    • 33646804507 scopus 로고    scopus 로고
    • Mechanisms of immune evasion by tumors
    • Drake C.G., Jaffee E., and Pardoll D.M. Mechanisms of immune evasion by tumors. Adv Immunol 90 (2006) 51-81
    • (2006) Adv Immunol , vol.90 , pp. 51-81
    • Drake, C.G.1    Jaffee, E.2    Pardoll, D.M.3
  • 11
    • 33750807427 scopus 로고    scopus 로고
    • CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients
    • Miller A.M., Lundberg K., Ozenci V., et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 177 (2006) 7398-7405
    • (2006) J Immunol , vol.177 , pp. 7398-7405
    • Miller, A.M.1    Lundberg, K.2    Ozenci, V.3
  • 12
    • 33748756028 scopus 로고    scopus 로고
    • TGF-beta: a mobile purveyor of immune privilege
    • Wahl S.M., Wen J., and Moutsopoulos N. TGF-beta: a mobile purveyor of immune privilege. Immunol Rev 213 (2006) 213-227
    • (2006) Immunol Rev , vol.213 , pp. 213-227
    • Wahl, S.M.1    Wen, J.2    Moutsopoulos, N.3
  • 13
    • 0141742297 scopus 로고    scopus 로고
    • Some interfaces of dendritic cell biology
    • Steinman R.M. Some interfaces of dendritic cell biology. APMIS 111 (2003) 675-697
    • (2003) APMIS , vol.111 , pp. 675-697
    • Steinman, R.M.1
  • 14
    • 34248204110 scopus 로고    scopus 로고
    • DC-based cancer vaccines
    • Gilboa E. DC-based cancer vaccines. J Clin Invest 117 (2007) 1195-1203
    • (2007) J Clin Invest , vol.117 , pp. 1195-1203
    • Gilboa, E.1
  • 15
    • 33748186518 scopus 로고    scopus 로고
    • Basic overview of current immunotherapy approaches in urologic malignancy
    • Drake C.G. Basic overview of current immunotherapy approaches in urologic malignancy. Urol Oncol 24 (2006) 413-418
    • (2006) Urol Oncol , vol.24 , pp. 413-418
    • Drake, C.G.1
  • 16
    • 33749606668 scopus 로고    scopus 로고
    • Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival
    • Thomas-Kaskel A.K., Zeiser R., Jochim R., et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer 119 (2006) 2428-2434
    • (2006) Int J Cancer , vol.119 , pp. 2428-2434
    • Thomas-Kaskel, A.K.1    Zeiser, R.2    Jochim, R.3
  • 17
    • 4344637057 scopus 로고    scopus 로고
    • Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study
    • Pandha H.S., John R.J., Hutchinson J., et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int 94 (2004) 412-418
    • (2004) BJU Int , vol.94 , pp. 412-418
    • Pandha, H.S.1    John, R.J.2    Hutchinson, J.3
  • 18
    • 33748142396 scopus 로고    scopus 로고
    • Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells
    • Lin A.M., Hershberg R.M., and Small E.J. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol 24 (2006) 434-441
    • (2006) Urol Oncol , vol.24 , pp. 434-441
    • Lin, A.M.1    Hershberg, R.M.2    Small, E.J.3
  • 19
    • 0034043167 scopus 로고    scopus 로고
    • Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer
    • Burch P.A., Breen J.K., Buckner J.C., et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 6 (2000) 2175-2182
    • (2000) Clin Cancer Res , vol.6 , pp. 2175-2182
    • Burch, P.A.1    Breen, J.K.2    Buckner, J.C.3
  • 20
    • 0034554863 scopus 로고    scopus 로고
    • Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
    • Small E.J., Fratesi P., Reese D.M., et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18 (2000) 3894-3903
    • (2000) J Clin Oncol , vol.18 , pp. 3894-3903
    • Small, E.J.1    Fratesi, P.2    Reese, D.M.3
  • 21
    • 33746012881 scopus 로고    scopus 로고
    • Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
    • Small E.J., Schellhammer P.F., Higano C.S., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24 (2006) 3089-3094
    • (2006) J Clin Oncol , vol.24 , pp. 3089-3094
    • Small, E.J.1    Schellhammer, P.F.2    Higano, C.S.3
  • 22
    • 0027538181 scopus 로고
    • Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
    • Dranoff G., Jaffee E., Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90 (1993) 3539-3543
    • (1993) Proc Natl Acad Sci U S A , vol.90 , pp. 3539-3543
    • Dranoff, G.1    Jaffee, E.2    Lazenby, A.3
  • 23
    • 0032741439 scopus 로고    scopus 로고
    • Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
    • Simons J.W., Mikhak B., Chang J.F., et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59 (1999) 5160-5168
    • (1999) Cancer Res , vol.59 , pp. 5160-5168
    • Simons, J.W.1    Mikhak, B.2    Chang, J.F.3
  • 24
    • 0032543225 scopus 로고    scopus 로고
    • CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells
    • Adler A.J., Marsh D.W., Yochum G.S., et al. CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J Exp Med 187 (1998) 1555-1564
    • (1998) J Exp Med , vol.187 , pp. 1555-1564
    • Adler, A.J.1    Marsh, D.W.2    Yochum, G.S.3
  • 25
    • 0030852624 scopus 로고    scopus 로고
    • Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells
    • Kurts C., Kosaka H., Carbone F.R., et al. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J Exp Med 186 (1997) 239-245
    • (1997) J Exp Med , vol.186 , pp. 239-245
    • Kurts, C.1    Kosaka, H.2    Carbone, F.R.3
  • 26
    • 0346984033 scopus 로고    scopus 로고
    • A phase I/II trial of high dose allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer
    • [abstract]
    • Simons J.W., Higano C., Corman J., et al. A phase I/II trial of high dose allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer. [abstract]. Proc Am Soc Clin Oncol 22 (2003) 166
    • (2003) Proc Am Soc Clin Oncol , vol.22 , pp. 166
    • Simons, J.W.1    Higano, C.2    Corman, J.3
  • 27
    • 34447650649 scopus 로고    scopus 로고
    • GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action
    • Simmons A.D., Li B., Gonzalez-Edick M., et al. GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action. Cancer Immunol Immunother 56 10 (2007) 1553-1565
    • (2007) Cancer Immunol Immunother , vol.56 , Issue.10 , pp. 1553-1565
    • Simmons, A.D.1    Li, B.2    Gonzalez-Edick, M.3
  • 28
    • 34447123763 scopus 로고    scopus 로고
    • Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer
    • Small E.J., Sacks N., Nemunaitis J., et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 13 (2007) 3883-3891
    • (2007) Clin Cancer Res , vol.13 , pp. 3883-3891
    • Small, E.J.1    Sacks, N.2    Nemunaitis, J.3
  • 30
    • 0032919654 scopus 로고    scopus 로고
    • Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer
    • Sanda M.G., Smith D.C., Charles L.G., et al. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 53 (1999) 260-266
    • (1999) Urology , vol.53 , pp. 260-266
    • Sanda, M.G.1    Smith, D.C.2    Charles, L.G.3
  • 31
    • 0036787490 scopus 로고    scopus 로고
    • Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer
    • Gulley J., Chen A.P., Dahut W., et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53 (2002) 109-117
    • (2002) Prostate , vol.53 , pp. 109-117
    • Gulley, J.1    Chen, A.P.2    Dahut, W.3
  • 32
    • 17444440950 scopus 로고    scopus 로고
    • A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer
    • Eder J.P., Kantoff P.W., Roper K., et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 6 (2000) 1632-1638
    • (2000) Clin Cancer Res , vol.6 , pp. 1632-1638
    • Eder, J.P.1    Kantoff, P.W.2    Roper, K.3
  • 33
    • 2942644684 scopus 로고    scopus 로고
    • Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group
    • Kaufman H.L., Wang W., Manola J., et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 22 (2004) 2122-2132
    • (2004) J Clin Oncol , vol.22 , pp. 2122-2132
    • Kaufman, H.L.1    Wang, W.2    Manola, J.3
  • 34
    • 30544449854 scopus 로고    scopus 로고
    • A phase I trial of pox PSA vaccines (PROSTVAC(R)-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOMtrade mark) in patients with prostate cancer
    • Dipaola R., Plante M., Kaufman H., et al. A phase I trial of pox PSA vaccines (PROSTVAC(R)-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOMtrade mark) in patients with prostate cancer. J Transl Med 4 (2006) 1
    • (2006) J Transl Med , vol.4 , pp. 1
    • Dipaola, R.1    Plante, M.2    Kaufman, H.3
  • 35
    • 34447136106 scopus 로고    scopus 로고
    • Cancer vaccines: moving beyond current paradigms
    • Schlom J., Arlen P.M., and Gulley J.L. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 13 (2007) 3776-3782
    • (2007) Clin Cancer Res , vol.13 , pp. 3776-3782
    • Schlom, J.1    Arlen, P.M.2    Gulley, J.L.3
  • 36
    • 34748847470 scopus 로고    scopus 로고
    • Enhancing efficacy of therapeutic vaccinations by combination with other modalities
    • [epub ahead of print]
    • Gulley J.L., Madan R.A., and Arlen P.M. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine (2007) [epub ahead of print]
    • (2007) Vaccine
    • Gulley, J.L.1    Madan, R.A.2    Arlen, P.M.3
  • 37
    • 2442585121 scopus 로고    scopus 로고
    • Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity
    • Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4 (2004) 336-347
    • (2004) Nat Rev Immunol , vol.4 , pp. 336-347
    • Chen, L.1
  • 38
    • 33646794392 scopus 로고    scopus 로고
    • Checkpoint blockade in cancer immunotherapy
    • Korman A.J., Peggs K.S., and Allison J.P. Checkpoint blockade in cancer immunotherapy. Adv Immunol 90 (2006) 297-339
    • (2006) Adv Immunol , vol.90 , pp. 297-339
    • Korman, A.J.1    Peggs, K.S.2    Allison, J.P.3
  • 39
    • 0035056017 scopus 로고    scopus 로고
    • CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy
    • Chambers C.A., Kuhns M.S., Egen J.G., et al. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19 (2001) 565-594
    • (2001) Annu Rev Immunol , vol.19 , pp. 565-594
    • Chambers, C.A.1    Kuhns, M.S.2    Egen, J.G.3
  • 40
    • 27444440093 scopus 로고    scopus 로고
    • Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer
    • Blansfield J.A., Beck K.E., Tran K., et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28 (2005) 593-598
    • (2005) J Immunother , vol.28 , pp. 593-598
    • Blansfield, J.A.1    Beck, K.E.2    Tran, K.3
  • 41
    • 34250223096 scopus 로고    scopus 로고
    • A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer
    • Small E.J., Tchekmedyian N.S., Rini B.I., et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13 (2007) 1810-1815
    • (2007) Clin Cancer Res , vol.13 , pp. 1810-1815
    • Small, E.J.1    Tchekmedyian, N.S.2    Rini, B.I.3
  • 42
    • 3042592452 scopus 로고    scopus 로고
    • The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy
    • Uchida J., Hamaguchi Y., Oliver J.A., et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199 (2004) 1659-1669
    • (2004) J Exp Med , vol.199 , pp. 1659-1669
    • Uchida, J.1    Hamaguchi, Y.2    Oliver, J.A.3
  • 43
    • 0242692683 scopus 로고    scopus 로고
    • Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen
    • Nanus D.M., Milowsky M.I., Kostakoglu L., et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 170 (2003) S84-S88
    • (2003) J Urol , vol.170
    • Nanus, D.M.1    Milowsky, M.I.2    Kostakoglu, L.3
  • 44
    • 4344618391 scopus 로고    scopus 로고
    • Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer
    • Milowsky M.I., Nanus D.M., Kostakoglu L., et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 22 (2004) 2522-2531
    • (2004) J Clin Oncol , vol.22 , pp. 2522-2531
    • Milowsky, M.I.1    Nanus, D.M.2    Kostakoglu, L.3
  • 45
    • 22044451179 scopus 로고    scopus 로고
    • Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
    • Bander N.H., Milowsky M.I., Nanus D.M., et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23 (2005) 4591-4601
    • (2005) J Clin Oncol , vol.23 , pp. 4591-4601
    • Bander, N.H.1    Milowsky, M.I.2    Nanus, D.M.3
  • 46
    • 20944441967 scopus 로고    scopus 로고
    • Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer
    • Gulley J.L., Arlen P.M., Bastian A., et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 11 (2005) 3353-3362
    • (2005) Clin Cancer Res , vol.11 , pp. 3353-3362
    • Gulley, J.L.1    Arlen, P.M.2    Bastian, A.3
  • 47
    • 22144472230 scopus 로고    scopus 로고
    • Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer
    • Arlen P.M., Gulley J.L., Todd N., et al. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol 174 (2005) 539-546
    • (2005) J Urol , vol.174 , pp. 539-546
    • Arlen, P.M.1    Gulley, J.L.2    Todd, N.3
  • 48
    • 33644760431 scopus 로고    scopus 로고
    • A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer
    • Arlen P.M., Gulley J.L., Parker C., et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12 (2006) 1260-1269
    • (2006) Clin Cancer Res , vol.12 , pp. 1260-1269
    • Arlen, P.M.1    Gulley, J.L.2    Parker, C.3
  • 49
    • 33745612716 scopus 로고    scopus 로고
    • The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration
    • Prell R.A., Gearin L., Simmons A., et al. The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration. Cancer Immunol Immunother 55 (2006) 1285-1293
    • (2006) Cancer Immunol Immunother , vol.55 , pp. 1285-1293
    • Prell, R.A.1    Gearin, L.2    Simmons, A.3
  • 50
    • 36048969172 scopus 로고    scopus 로고
    • 2007 ASCO Annual Meeting Proceedings, Part I
    • Gerritsen W.R. 2007 ASCO Annual Meeting Proceedings, Part I. J Clin Oncol 25 Suppl 18S0 (2007) 5120
    • (2007) J Clin Oncol , vol.25 , Issue.SUPPL. 18S0 , pp. 5120
    • Gerritsen, W.R.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.